NeoGenomics (NEO) Stock Forecast, Price Target & Predictions
NEO Stock Forecast
NeoGenomics stock forecast is as follows: an average price target of $23.00 (represents a 40.24% upside from NEO’s last price of $16.40) and a rating consensus of 'Buy', based on 8 wall street analysts offering a 1-year stock forecast.
NEO Price Target
The average price target for NeoGenomics (NEO) is $23.00 based on 1-year price targets from 8 Wall Street analysts in the past 3 months, with a price target range of $54.00 to $15.00. This represents a potential 40.24% upside from NEO's last price of $16.40.
NEO Analyst Ratings
According to 8 Wall Street analysts, NeoGenomics's rating consensus is 'Buy'. The analyst rating breakdown for NEO stock is 0 'Strong Buy' (0.00%), 7 'Buy' (87.50%), 1 'Hold' (12.50%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
NeoGenomics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jul 30, 2024 | Mike Matson | Needham | $19.00 | $14.64 | 29.78% | 15.85% |
| May 02, 2024 | Mark Massaro | BTIG | $21.00 | $13.96 | 50.43% | 28.05% |
| Aug 21, 2023 | Mason Carrico | Stephens | $18.00 | $14.08 | 27.84% | 9.76% |
| Aug 17, 2022 | David Westenberg | Piper Sandler | $19.00 | $11.64 | 63.23% | 15.85% |
| Aug 10, 2022 | - | Morgan Stanley | $18.00 | $11.66 | 54.37% | 9.76% |
| Aug 10, 2022 | - | Goldman Sachs | $20.00 | $11.59 | 72.56% | 21.95% |
| Aug 10, 2022 | - | Needham | $16.00 | $11.68 | 36.99% | -2.44% |
| Apr 28, 2022 | - | Raymond James | $15.00 | $10.44 | 43.68% | -8.54% |
| Jun 03, 2021 | Matthew Sykes | Goldman Sachs | $55.00 | $40.11 | 37.12% | 235.37% |
| May 25, 2021 | Sandy Draper | Guggenheim | $54.00 | $39.17 | 37.86% | 229.27% |
The latest NeoGenomics stock forecast, released on Jul 30, 2024 by Mike Matson from Needham, set a price target of $19.00, which represents a 29.78% increase from the stock price at the time of the forecast ($14.64), and a 15.85% increase from NEO last price ($16.40).
NeoGenomics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 2 |
| Avg Price Target | - | $19.00 | $20.00 |
| Last Closing Price | $16.40 | $16.40 | $16.40 |
| Upside/Downside | -100.00% | 15.85% | 21.95% |
In the current month, the average price target of NeoGenomics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to NeoGenomics's last price of $16.40. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Jul 30, 2024 | Needham | Buy | Buy | Hold |
| May 02, 2024 | BTIG | Buy | Buy | Hold |
| Mar 18, 2024 | Piper Sandler | Buy | Buy | Hold |
| Feb 22, 2024 | Goldman Sachs | Buy | Buy | Hold |
| Feb 21, 2024 | Needham | Buy | Buy | Hold |
| Feb 21, 2024 | Cowen & Co. | Underperform | Underperform | Hold |
| Dec 29, 2023 | Cowen & Co. | Outperform | Outperform | Hold |
| Dec 28, 2023 | Piper Sandler | Buy | Buy | Hold |
| Aug 21, 2023 | Stephens | - | Overweight | Upgrade |
| May 09, 2023 | BTIG | - | Buy | Upgrade |
NeoGenomics's last stock rating was published by Needham on Jul 30, 2024. The company gave NEO a "Buy" rating, the same as its previous rate.
NeoGenomics Financial Forecast
NeoGenomics Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | $151.95M | $146.92M | $137.22M | $138.71M | $128.78M | $125.07M | $117.17M | $125.73M | $121.34M | $121.72M | $115.53M | $126.00M | $125.44M | $86.98M | $106.03M | $106.87M | $104.67M |
| Avg Forecast | $207.56M | $198.17M | $196.45M | $186.82M | $190.11M | $182.52M | $180.17M | $171.70M | $173.81M | $167.01M | $161.82M | $149.85M | $152.54M | $141.67M | $137.45M | $129.27M | $129.97M | $121.54M | $122.93M | $116.71M | $125.74M | $124.56M | $121.47M | $112.14M | $123.65M | $126.22M | $86.55M | $105.24M | $104.25M | $99.38M |
| High Forecast | $209.35M | $199.88M | $198.15M | $188.44M | $191.75M | $184.10M | $181.73M | $173.18M | $175.31M | $168.24M | $163.21M | $151.14M | $155.35M | $145.93M | $138.64M | $130.38M | $131.09M | $122.59M | $124.11M | $117.84M | $126.95M | $125.76M | $122.64M | $113.22M | $124.84M | $127.44M | $87.39M | $106.25M | $105.26M | $100.34M |
| Low Forecast | $203.74M | $194.52M | $192.84M | $183.38M | $186.61M | $179.16M | $176.85M | $168.54M | $170.61M | $164.44M | $158.84M | $147.09M | $148.65M | $138.18M | $134.92M | $126.89M | $127.57M | $119.30M | $121.34M | $115.20M | $124.11M | $122.95M | $119.89M | $110.69M | $122.05M | $124.59M | $85.43M | $103.87M | $102.90M | $98.10M |
| # Analysts | 6 | 6 | 12 | 11 | 10 | 9 | 8 | 7 | 13 | 6 | 3 | 3 | 6 | 11 | 5 | 9 | 5 | 4 | 4 | 7 | 5 | 5 | 10 | 7 | 5 | 10 | 10 | 10 | 9 | 9 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.07% | 1.07% | 1.06% | 1.07% | 1.06% | 1.02% | 1.00% | 1.00% | 0.97% | 1.00% | 1.03% | 1.02% | 0.99% | 1.00% | 1.01% | 1.03% | 1.05% |
NeoGenomics's average Quarter revenue forecast for Dec 23 based on 6 analysts is $152.54M, with a low forecast of $148.65M, and a high forecast of $155.35M. NEO's average Quarter revenue forecast represents a 0.39% increase compared to the company's last Quarter revenue of $151.95M (Sep 23).
NeoGenomics EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 6 | 6 | 12 | 11 | 10 | 9 | 8 | 7 | 13 | 6 | 3 | 3 | 6 | 11 | 5 | 9 | 5 | 4 | 4 | 7 | 5 | 5 | 10 | 7 | 5 | 10 | 10 | 10 | 9 | 9 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | $-24.20M | $-29.89M | $-7.87M | $-23.31M | $-22.02M | $-22.69M | $-35.14M | $-25.64M | $-5.22M | $85.04M | $-10.82M | $19.39M | $13.68M | $-3.10M | $3.62M | $10.40M | $10.92M |
| Avg Forecast | $3.49M | $3.33M | $3.30M | $3.14M | $3.20M | $3.07M | $3.03M | $2.89M | $2.92M | $2.81M | $2.72M | $-51.40M | $2.56M | $2.38M | $2.31M | $-46.73M | $2.18M | $-5.27M | $2.07M | $-42.48M | $2.11M | $2.09M | $2.04M | $-58.44M | $2.08M | $2.12M | $1.45M | $9.78M | $1.75M | $1.67M |
| High Forecast | $3.52M | $3.36M | $3.33M | $3.17M | $3.22M | $3.09M | $3.05M | $2.91M | $2.95M | $2.83M | $2.74M | $-41.12M | $2.61M | $2.45M | $2.33M | $-37.38M | $2.20M | $-4.21M | $2.09M | $-33.98M | $2.13M | $2.11M | $2.06M | $-46.76M | $2.10M | $2.14M | $1.47M | $11.74M | $1.77M | $1.69M |
| Low Forecast | $3.42M | $3.27M | $3.24M | $3.08M | $3.14M | $3.01M | $2.97M | $2.83M | $2.87M | $2.76M | $2.67M | $-61.68M | $2.50M | $2.32M | $2.27M | $-56.07M | $2.14M | $-6.32M | $2.04M | $-50.97M | $2.09M | $2.07M | $2.02M | $-70.13M | $2.05M | $2.09M | $1.44M | $7.82M | $1.73M | $1.65M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | -10.16% | -12.94% | 0.17% | -10.67% | 4.18% | -10.98% | 0.83% | -12.13% | -2.49% | 41.66% | 0.19% | 9.33% | 6.45% | -2.13% | 0.37% | 5.94% | 6.54% |
5 analysts predict NEO's average Quarter EBITDA for Sep 21 to be $2.09M, with a high of $2.11M and a low of $2.07M. This is -97.54% lower than NeoGenomics's previous annual EBITDA (Jun 21) of $85.04M.
NeoGenomics Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 6 | 6 | 12 | 11 | 10 | 9 | 8 | 7 | 13 | 6 | 3 | 3 | 6 | 11 | 5 | 9 | 5 | 4 | 4 | 7 | 5 | 5 | 10 | 7 | 5 | 10 | 10 | 10 | 9 | 9 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | $-18.52M | $-24.33M | $-30.80M | $-22.69M | $-36.85M | $-35.30M | $-49.41M | $-41.76M | $-20.35M | $75.87M | $-22.11M | $15.42M | $2.56M | $-6.82M | $-6.98M | $6.30M | $2.14M |
| Avg Forecast | $14.98M | $10.43M | $11.15M | $6.63M | $9.69M | $6.21M | $6.61M | $2.43M | $4.33M | $1.53M | $-391.86K | $-67.58M | $-3.12M | $-9.43M | $-14.42M | $-61.44M | $-20.81M | $-20.52M | $-29.65M | $-55.85M | $-19.08M | $-11.38M | $-1.69M | $-119.42M | $7.55M | $4.80M | $-13.11M | $-18.84M | $8.13M | $7.58M |
| High Forecast | $15.15M | $10.55M | $11.27M | $6.70M | $9.80M | $6.28M | $6.69M | $2.46M | $8.67M | $4.60M | $-382.48K | $-54.07M | $-3.05M | $-5.90M | $-14.08M | $-49.15M | $-20.31M | $-16.41M | $-29.15M | $-44.68M | $-18.75M | $-11.19M | $-1.66M | $-95.53M | $7.64M | $4.86M | $-12.89M | $-15.07M | $8.23M | $7.68M |
| Low Forecast | $14.62M | $10.18M | $10.88M | $6.47M | $9.46M | $6.07M | $6.45M | $2.37M | $1.44M | $-4.60M | $-396.25K | $-81.10M | $-3.16M | $-18.87M | $-14.59M | $-73.73M | $-21.04M | $-24.62M | $-30.02M | $-67.02M | $-19.31M | $-11.52M | $-1.71M | $-143.30M | $7.42M | $4.72M | $-13.28M | $-22.61M | $7.99M | $7.46M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.96% | 1.69% | 0.50% | 1.09% | 1.80% | 1.19% | 0.88% | 2.19% | 1.79% | -45.02% | 0.19% | 2.04% | 0.53% | 0.52% | 0.37% | 0.77% | 0.28% |
NeoGenomics's average Quarter net income forecast for Sep 21 is $-11.38M, with a range of $-11.52M to $-11.19M. NEO's average Quarter net income forecast represents a -114.99% decrease compared to the company's last Quarter net income of $75.87M (Jun 21).
NeoGenomics SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 6 | 6 | 12 | 11 | 10 | 9 | 8 | 7 | 13 | 6 | 3 | 3 | 6 | 11 | 5 | 9 | 5 | 4 | 4 | 7 | 5 | 5 | 10 | 7 | 5 | 10 | 10 | 10 | 9 | 9 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | $79.10M | $79.21M | $77.81M | $75.00M | $81.09M | $75.02M | $82.55M | $78.31M | $79.54M | $71.86M | $54.23M | $49.81M | $47.43M | $44.81M | $49.60M | $45.52M | $44.56M |
| Avg Forecast | $107.37M | $102.51M | $101.62M | $96.64M | $98.34M | $94.42M | $93.20M | $88.82M | $89.91M | $86.39M | $83.71M | $112.91M | $78.91M | $73.29M | $71.10M | $102.65M | $67.23M | $80.21M | $63.59M | $93.31M | $65.05M | $64.44M | $62.83M | $58.01M | $63.96M | $65.30M | $44.77M | $54.44M | $53.93M | $51.41M |
| High Forecast | $108.30M | $103.40M | $102.50M | $97.48M | $99.19M | $95.23M | $94.01M | $89.59M | $90.69M | $87.03M | $84.43M | $135.49M | $80.36M | $75.49M | $71.72M | $123.17M | $67.81M | $96.25M | $64.20M | $111.98M | $65.67M | $65.06M | $63.44M | $58.57M | $64.58M | $65.93M | $45.21M | $54.96M | $54.45M | $51.91M |
| Low Forecast | $105.39M | $100.63M | $99.75M | $94.86M | $96.53M | $92.68M | $91.49M | $87.18M | $88.26M | $85.06M | $82.17M | $90.33M | $76.90M | $71.48M | $69.79M | $82.12M | $65.99M | $64.16M | $62.77M | $74.65M | $64.20M | $63.60M | $62.02M | $57.26M | $63.14M | $64.45M | $44.20M | $53.73M | $53.23M | $50.74M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.08% | 1.11% | 0.76% | 1.12% | 1.01% | 1.18% | 0.88% | 1.20% | 1.23% | 1.14% | 0.93% | 0.78% | 0.73% | 1.00% | 0.91% | 0.84% | 0.87% |
NeoGenomics's average Quarter SG&A projection for Dec 23 is $78.91M, based on 6 Wall Street analysts, with a range of $76.90M to $80.36M. The forecast indicates a -0.23% fall compared to NEO last annual SG&A of $79.10M (Sep 23).
NeoGenomics EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 6 | 6 | 12 | 11 | 10 | 9 | 8 | 7 | 13 | 6 | 3 | 3 | 6 | 11 | 5 | 9 | 5 | 4 | 4 | 7 | 5 | 5 | 10 | 7 | 5 | 10 | 10 | 10 | 9 | 9 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | $-0.15 | $-0.19 | $-0.25 | $-0.18 | $-0.30 | $-0.28 | $-0.40 | $-0.34 | $-0.17 | $0.64 | $-0.19 | $0.14 | $0.02 | $-0.06 | $-0.07 | $0.06 | $0.02 |
| Avg Forecast | $0.12 | $0.08 | $0.09 | $0.05 | $0.08 | $0.05 | $0.05 | $0.02 | $0.03 | $0.01 | $-0.00 | $-0.04 | $-0.02 | $-0.07 | $-0.11 | $-0.14 | $-0.16 | $-0.21 | $-0.23 | $-0.24 | $-0.15 | $-0.09 | $-0.01 | $0.01 | $0.06 | $0.04 | $-0.10 | $0.02 | $0.06 | $0.06 |
| High Forecast | $0.12 | $0.08 | $0.09 | $0.05 | $0.08 | $0.05 | $0.05 | $0.02 | $0.07 | $0.04 | $-0.00 | $-0.04 | $-0.02 | $-0.05 | $-0.11 | $-0.14 | $-0.16 | $-0.20 | $-0.23 | $-0.23 | $-0.15 | $-0.09 | $-0.01 | $0.01 | $0.06 | $0.04 | $-0.10 | $0.02 | $0.07 | $0.06 |
| Low Forecast | $0.12 | $0.08 | $0.09 | $0.05 | $0.07 | $0.05 | $0.05 | $0.02 | $0.01 | $-0.04 | $-0.00 | $-0.04 | $-0.02 | $-0.15 | $-0.12 | $-0.14 | $-0.17 | $-0.21 | $-0.24 | $-0.24 | $-0.15 | $-0.09 | $-0.01 | $0.01 | $0.06 | $0.04 | $-0.11 | $0.02 | $0.06 | $0.06 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.01% | 1.67% | 1.79% | 1.09% | 1.46% | 1.19% | 1.68% | 2.25% | 1.89% | -48.00% | -21.26% | 2.34% | 0.53% | 0.61% | -3.56% | 0.93% | 0.33% |
According to 5 Wall Street analysts, NeoGenomics's projected average Quarter EPS for Sep 21 is $-0.09, with a low estimate of $-0.09 and a high estimate of $-0.09. This represents a -114.06% decrease compared to NEO previous annual EPS of $0.64 (Jun 21).
NeoGenomics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| ACRS | Aclaris Therapeutics | $1.18 | $25.00 | 2018.64% | Buy |
| GH | Guardant Health | $26.79 | $57.27 | 113.77% | Buy |
| BDSX | Biodesix | $1.77 | $3.00 | 69.49% | Buy |
| CRL | Charles River Laboratories | $198.61 | $324.46 | 63.37% | Buy |
| NEO | NeoGenomics | $16.40 | $23.00 | 40.24% | Buy |
| CSTL | Castle Biosciences | $31.18 | $38.00 | 21.87% | Buy |
| QGEN | Qiagen | $46.36 | $52.37 | 12.96% | Buy |
| IQV | IQVIA | $238.70 | $269.43 | 12.87% | Buy |
| NEOG | Neogen | $16.13 | $17.50 | 8.49% | Buy |
| CDNA | CareDx | $28.87 | $31.00 | 7.38% | Buy |
| ICLR | ICON Public Limited Company | $300.00 | $307.63 | 2.54% | Buy |
| SHC | Sotera Health Company | $16.80 | $16.93 | 0.77% | Buy |
| MYGN | Myriad Genetics | $27.59 | $27.67 | 0.29% | Hold |
| MTD | Mettler-Toledo | $1.38K | $1.36K | -1.35% | Hold |
| NTRA | Natera | $126.51 | $114.38 | -9.59% | Buy |
| TWST | Twist Bioscience | $46.95 | $41.20 | -12.25% | Buy |
| OLK | Olink AB (publ) | $26.08 | $21.50 | -17.56% | Hold |
NEO Forecast FAQ
Is NeoGenomics a good buy?
Yes, according to 8 Wall Street analysts, NeoGenomics (NEO) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 7 'Buy' recommendations, accounting for 87.50% of NEO's total ratings.
What is NEO's price target?
NeoGenomics (NEO) average price target is $23 with a range of $15 to $54, implying a 40.24% from its last price of $16.4. The data is based on 8 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will NeoGenomics stock go up soon?
According to Wall Street analysts' prediction for NEO stock, the company can go up by 40.24% (from the last price of $16.4 to the average price target of $23), up by 229.27% based on the highest stock price target, and down by -8.54% based on the lowest stock price target.
Can NeoGenomics stock reach $20?
NEO's average twelve months analyst stock price target of $23 supports the claim that NeoGenomics can reach $20 in the near future.
What are NeoGenomics's analysts' financial forecasts?
NeoGenomics's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $724.5M (high $730.75M, low $711.16M), average EBITDA is $12.18M (high $12.28M, low $11.95M), average net income is $24.95M (high $25.23M, low $24.35M), average SG&A $374.78M (high $378.02M, low $367.88M), and average EPS is $0.197 (high $0.2, low $0.193). NEO's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $789.01M (high $795.82M, low $774.48M), average EBITDA is $13.26M (high $13.38M, low $13.02M), average net income is $43.19M (high $43.67M, low $42.15M), average SG&A $408.15M (high $411.67M, low $400.64M), and average EPS is $0.342 (high $0.345, low $0.333).
Did the NEO's actual financial results beat the analysts' financial forecasts?
Based on NeoGenomics's last annual report (Dec 2022), the company's revenue was $509.73M, beating the average analysts forecast of $491.15M by 3.78%. Apple's EBITDA was $-83.89M, beating the average prediction of $-43.493M by 92.88%. The company's net income was $-144M, beating the average estimation of $-127M by 13.74%. Apple's SG&A was $310.68M, beating the average forecast of $304.34M by 2.08%. Lastly, the company's EPS was $-1.16, beating the average prediction of $-0.843 by 37.61%. In terms of the last quarterly report (Sep 2023), NeoGenomics's revenue was $151.95M, beating the average analysts' forecast of $141.67M by 7.26%. The company's EBITDA was $-24.195M, missing the average prediction of $2.38M by -1116.13%. NeoGenomics's net income was $-18.516M, beating the average estimation of $-9.433M by 96.30%. The company's SG&A was $79.1M, beating the average forecast of $73.29M by 7.93%. Lastly, the company's EPS was $-0.15, beating the average prediction of $-0.0746 by 101.01%